A pioneering study marks a major step toward eliminating the need for daily insulin injections for people with diabetes. The ...
Subcutaneous anifrolumab is superior to placebo in multiple systemic lupus erythematosus disease activity measures at 52 weeks, according to data published in Arthritis & Rheumatology.“As a ...
The FDA has accepted Alvotech (NASDAQ:ALVO) and Teva's (NYSE:TEVA) Biologics License Applications for AVT05, their proposed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results